Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)
Phase 1
Completed
- Conditions
- Duchenne's Muscular Dystrophy
- Interventions
- Biological: Umbilical Cord Mesenchymal Stem Cells
- Registration Number
- NCT02235844
- Lead Sponsor
- Allergy and Asthma Consultants, Wichita, Kansas
- Brief Summary
This research study is designed to evaluate the effects of human umbilical cord mesenchymal stem cells (UC-MSCs), on Duchenne's muscular dystrophy (DMD). The potential muscle regenerative and anti-inflammatory properties of UC MSCs position them as a possible treatment option for DMD. Both of these properties could lead to potential benefits for a DMD patient.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1
Inclusion Criteria
- Duchenne's Muscular Dystrophy
Exclusion Criteria
- None
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Mesenchymal Stem Cells Umbilical Cord Mesenchymal Stem Cells Umbilical Cord Mesenchymal Stem Cells
- Primary Outcome Measures
Name Time Method Adverse Events 3 months after final treatment No occurrence of adverse events
- Secondary Outcome Measures
Name Time Method Change from baseline of weight 3 months after final treatment Change from baseline of Pulmonary Maximum Expiratory Pressure 3 months after final treatment Change from baseline of Pulmonary Forced Vital Capacity 3 months after final treatment Change of muscle diameter (circumferential measurements) from baseline 3 months after final treatment Maximum Change from baseline of Predicted Inspiratory Pressure % 3 months after final treatment Change from baseline of Predicted Maximum Expiratory Pressure % 3 months after final treatment Change from baseline of Predicted Forced Vital Capacity % 3 months after final treatment
Trial Locations
- Locations (1)
Asthma and Allergy Consultants
🇺🇸Wichita, Kansas, United States